Evaxion Biotech (EVAX) obtains preclinical Proof-of-Concept, PoC, for its precision cancer vaccine concept targeting non-conventional ERV tumor antigens shared across patients. New data confirming the preclinical PoC is presented at the ESMO Immuno-Oncology Congress, currently taking place in Geneva, Switzerland. Evaxion’s AI-Immunologyplatform can identify and select vaccine targets from ERVs expressed in the cancer cells, enabling the design of precision cancer vaccines for multiple specific cancer types.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech announces strategic milestones for 2025
- Evaxion Biotech Unveils 2025 Strategic Milestones
- Evaxion Biotech Unveils Precision Cancer Vaccine Breakthrough
- Evaxion to present preclinical proof-of-concept for ERV cancer vaccine concept
- Evaxion Biotech files to sell 5.25M American Depositary Shares